Evidence map›Paper›PMID 31938050›Full record

ArticleTheranostics2020

Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2-mediated uridine-cytidine kinase 1 degradation and confers sensitivity to 5'-azacytidine-resistant human leukemia cells.

Heng Zhang, He Huang, Xing Feng, Huiwen Song, Zhiyong Zhang, Aizong Shen, Xingfeng Qiu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. The roles of KLHL family members in human cancers.American journal of cancer research · 2022
    Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Heng ZhangDepartment of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, Hunan, China.
He HuangDepartment of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, Hunan, China.
Xing FengThe affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China.
Huiwen SongDepartment of Cardiology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China.
Zhiyong ZhangNational Center for International Research of Biological Targeting Diagnosis and Therapy (Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research), Guangxi Medical University, Nanning, China.
Aizong ShenPharmacy Department, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Xingfeng QiuDepartment of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, Xiamen, Fujian, China.
Central South University · CNGuilin Medical University · CNJiading District Central Hospital · CNRobert Wood Johnson University Hospital · USUniversity of Science and Technology of China · CNZhongshan Hospital of Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to the chemotherapeutic drug 5'-azacytidine (5'-AZA) is a major obstacle in the treatment of patients with acute myeloid leukemia (AML). The uridine-cytidine kinase 1 (UCK1) has an established role in activating 5'-AZA and its protein level is significantly downregulated in patients resistant to the drug. However, the underlying molecular mechanism for the reduced UCK1 expression remains to be elucidated.

Indexed as

AzacitidineDrug Resistance, NeoplasmEnzyme InhibitorsLeukemia, Myeloid, AcuteAnimalsAtaxia Telangiectasia Mutated ProteinsHEK293 CellsHL-60 CellsHumansMaleMiceMice, Inbred NODMice, SCIDMicrofilament ProteinsNerve Tissue ProteinsUbiquitin ThiolesteraseAtaxia Telangiectasia Mutated ProteinsATM protein, humanAzacitidineEnzyme InhibitorsKLHL2 protein, humanMicrofilament ProteinsNerve Tissue ProteinsUbiquitin ThiolesteraseUridine KinaseUSP28 protein, human5'-AZAKLHL2ubiquitinationUCK1USP28

Identifiers

PMID31938050
PMCPMC6956814
OpenAlexW2994046320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.